https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
e HCV-viremic donor organs did not differ from the HCV-negative donor organs or impact graft and recipient survival. Due to an increasing number of transplants from increased risk donors and in order to develop safe and effective protocols to perform lung transplants from HCV-infected donors, further characterization of the donor and allograft-specific clinical features and longer-term recipient outcomes is greatly needed. 2020 Annals of Cardiothoracic Surgery. All rights reserved.The introduction of the lung allocation scor
Like
Comment
Share
